新冠病毒病患者中抗核抗体的流行率：与健康对照相比显著升高了2.5倍。

Prevalence of anti-nuclear antibodies in COVID-19 patients: a remarkable 2.5-fold rise compared to healthy controls.

作者信息

Dişli Faruk, Yıldız Sedat

机构信息

Faculty of Physiotherapy and Rehabilitation Department of Basic Physiotherapy, Bingöl University, Bingöl, Türkiye.

Faculty of Medicine, Department of Physiology, İnönü University, Malatya, Türkiye.

出版信息

Ir J Med Sci. 2025 Apr;194(2):717-724. doi: 10.1007/s11845-025-03886-8. Epub 2025 Feb 1.

DOI:10.1007/s11845-025-03886-8

PMID:39891878

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12031873/

Abstract

BACKGROUND

The SARS-CoV-2 virus, responsible for COVID-19, has the potential to induce the formation of antibodies that target self-antigens. This study aimed to investigate the prevalence of antinuclear antibodies (ANA), the most common type of autoantibody, in both healthy individuals and those recovered from COVID-19.

METHODS

This retrospective study involved 400 participants (200 with COVID-19 and 200 healthy controls), aged 18 to 60 years, without any chronic diseases, including autoimmune conditions. Analyses were performed using three different ANA ELISA test kits (anti-dsDNA, anti-ENA, and anti-Hep-2 nucleus tests) that were developed and validated.

RESULTS

Among the 200 healthy individuals, 38 (19%) tested positive for dsDNA, 37 (18.5%) for ENA, and 30 (15%) for Hep-2 nucleus antibodies. The rates of ANA positivity were significantly higher in individuals with COVID-19, with 97 (48.5%) positive for dsDNA, 81 (40.5%) for ENA, and 84 (42%) for Hep-2 nucleus antibodies (p < 0.05).

CONCLUSION

One in every two to three individuals with COVID-19 exhibited ANA positivity, indicating that the SARS-CoV-2 virus poses a significant risk regarding autoimmunity. Furthermore, the incidence of ANA in healthy individuals was observed to be higher than the literature average.

摘要

背景

导致COVID-19的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒有可能诱导针对自身抗原的抗体形成。本研究旨在调查健康个体和COVID-19康复者中最常见的自身抗体类型——抗核抗体（ANA）的流行情况。

方法

这项回顾性研究纳入了400名年龄在18至60岁之间、无任何慢性疾病（包括自身免疫性疾病）的参与者（200名COVID-19患者和200名健康对照）。使用三种经过开发和验证的不同ANA酶联免疫吸附试验试剂盒（抗双链DNA、抗可提取核抗原和抗人喉癌上皮细胞系核试验）进行分析。

结果

在200名健康个体中，38人（19%）抗双链DNA检测呈阳性，37人（18.5%）抗可提取核抗原检测呈阳性，30人（15%）抗人喉癌上皮细胞系核抗体检测呈阳性。COVID-19患者的ANA阳性率显著更高，其中97人（48.5%）抗双链DNA阳性，81人（40.5%）抗可提取核抗原阳性，84人（42%）抗人喉癌上皮细胞系核抗体阳性（p<0.05）。